Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

By afschroeder • December 4, 2025

Merryman RW, Rutherford SC, Ansell SM, Armand P, Leonard JP, Nastoupil L, Smith SM, Timmerman JM, Zelenetz AD, Gutierrez M, Béguelin W, Casulo C, Cerhan JR, Green MR, Kahl BS, Kridel R, Link BK, Maurer MJ, Nadel B, Radtke A, Luttwak E, Salles GA, Sehn LH, Pasqualucci L, LaCasce AS. Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop. Blood Adv. 2025 Dec 3:bloodadvances.2025018079. doi: 10.1182/bloodadvances.2025018079. Epub ahead of print. PMID: 41337699.

Tags: Hematology/Oncology, Publications

Related Posts

Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer

Jacob S, Fisch S, Face C, Blum K, Chengappa M, Chaudhry S, LeVee A, Baclig NV, Soliman A, Huppert LA, Quandt Z, Quintal L, Idossa[...]

A Pilot Test of an AI Voice-Driven Simulation With Feedback for Medical Students to Practice Discussing Diagnostic Mammogram Results With Patients

Comulada WS, Ganz PA, Huang YM, Weisman D, Sugarman A, Lee D, Shah S, Gelberg L. A Pilot Test of an AI Voice-Driven Simulation With[...]

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B, Barrios CH, Untch M, Moroose[...]